Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis receives warning from FDA
The letter relates to deficiencies in the way that Actavis has handled its adverse medical event reporting obligations and also questions the marketing status of certain of Actavis’s
The letter relates to deficiencies in the way that Actavis has handled its adverse medical event reporting obligations and also questions the marketing status of certain of Actavis’s
The pivotal study will include a maximum of 273 patients with squamous cell carcinoma of the head and neck (SCCHN) who are refractory to or intolerant of standard
The in vitro portion of this testing will require approximately six months to complete at which time the in vivo testing will begin. After six months of this
GE Bayer Silicones is a part of GE Advanced Materials, which GE earlier announced it is selling to New York-based Apollo Management for $3.8 billion. Bayer said that
The study findings point to talabostat’s ability to stimulate key cytokines known to play an important role in immunostimulation – the enhancement of the body’s natural defenses against
Upstream, which aims to become an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is developing diagnostic tests that may
GX15-070 is specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, thus restoring the natural cell death process of apoptosis. Phase
During the one month safety and tolerability study for the drug, several cases of asymptomatic elevated liver function tests in the group of elderly volunteers were observed. No
Under the separate settlements with Watson Pharmaceuticals and Par Pharmaceutical Companies, a generic version of the gel will be marketed beginning in 2015, approximately five years before the
For the 300mg dosing group, 61% of patients receiving the drug completed the study in normal heart rhythm, as compared to 43% of all patients receiving placebo, with